14 February 2023 in Heliyon
Immune checkpoint inhibitor monoclonal antibodies allow the host's immune system to attack tumors, which has revolutionized cancer care over the last decade. As the use of immune checkpoint inhibitors has expanded, so have autoimmune-like complications known as immune-related adverse events. These include the infrequent but increasingly more common, potentially deadly neurological immune related adverse events. When feeling acutely ill, patients will often seek care not from their oncologist but from their family physician, clinics, emergency, and urgent care sites, or other available providers. Thus, while assessing acutely ill cancer patients who are experiencing neurological symptoms, non-oncologists should be prepared to recognize, diagnose, and treat neurological immune related adverse events in addition to more familiar conditions. This narrative review is designed to update acute care clinicians on current knowledge and to present a symptom-based framework for evaluating and treating neurological immune related adverse events based on the leading immunotoxicity organizations' latest recommendations.
1 February 2021 in Annals of Palliative Medicine
Characteristics of cancer patients with COVID-19 in a cancer hospital Demis N. Lipe, Ahmed Elsayem, Maria T. Cruz-Carreras, Jomol Thomas, Adianes Feliciano, Jenny Ren, Susan M. Gaeta, Eva Rajha, Elisabet Manasanch, Ed Kheder, Patricia Brock, Cielito Reyes-Gibby
1 September 2016 in The American Journal of Emergency Medicine
1 April 2018 in Acute Medicine Journal
Treatment of human immunodeficiency virus(HIV) in cancer patients improves outcomes and reduces transmission of this oncogenic virus. HIV testing rates of cancer patients are similar to the general population (15-40%), despite the association with cancer. Our aim was to increase HIV screening in the Emergency Department(ED) of a comprehensive cancer center through a quality initiative. Testing increased significantly during the intervention (p
11 October 2025 in JACEP Open
Longer boarding time in emergency departments (EDs) has been associated with negative clinical outcomes, including higher mortality rates. Studies of boarding to date have been conducted in the general population but not in the cancer population. In this study, we evaluated the association between mortality and boarding time in patients presenting at an oncologic ED. This retrospective study included all ED visits for patients aged ≥19 years who presented to The University of Texas MD Anderson Cancer Center ED between March 3, 2016 and December 31, 2022, with a disposition of hospital admission. Univariate and multivariable logistic regression analyses were performed to determine the associations between boarding time and in-hospital mortality. The final patient cohort included 43,308 patients. The median boarding time was 2.7 hours (interquartile range = 1.5-5.2 hours), with an in-hospital mortality rate of 7.0% (n = 3029). Death occurred in 6.9% of patients (n = 2997) within 14 days of ED presentation and increased to 13.7% (n = 5941) within 30 days. Patients with boarding times ≥5.2 hours had a 24% higher odds of in-hospital mortality compared with patients with <1.5 hours (odds ratio = 1.24; 95% confidence interval = 1.11-1.38; P < .001) after controlling for common clinical and cancer-related factors. Longer ED boarding times were associated with higher in-hospital mortality rates after hospital admission. These results emphasize the need for improved strategies to expedite the admission process and optimize care transitions for cancer patients in the ED to reduce mortality rates, especially for patients with complex medical needs and high-acuity presentations.